Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type 2 selected

Type

Guidance programme 6 selected

Guidance programme

Showing 1 to 10 of 1118

TitleReference numberPublishedLast updated
Bimekizumab for treating moderate to severe hidradenitis suppurativa (terminated appraisal)TA1028
Andexanet alfa for reversing anticoagulation in people with intracranial haemorrhage (terminated appraisal)TA1029
Durvalumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancerTA1030
Andexanet alfa for reversing anticoagulation from apixaban or rivaroxabanTA697
Maternal and child nutrition: nutrition and weight management in pregnancy, and nutrition in children up to 5 yearsNG247
Overweight and obesity managementNG246
Tebentafusp for treating advanced uveal melanomaTA1027
Tirzepatide for managing overweight and obesityTA1026
Ublituximab for treating relapsing multiple sclerosisTA1025
Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatmentsTA1023

Results per page

  1. 10
  2. 25
  3. 50
  4. All